SERPINH1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL17491642	0.75	2/20
SCHEMBL7254885	0.59	2/20
SCHEMBL28551820	0.57	2/20
SCHEMBL7613647	0.56	2/20
SCHEMBL7258556	0.56	2/20
SCHEMBL10719405	0.55	2/20
SCHEMBL11524389	0.54	2/20
SCHEMBL7606379	0.53	2/20
SCHEMBL2672236	0.52	2/20
SCHEMBL30605805	0.52	2/20
SCHEMBL7255927	0.51	2/20
SCHEMBL1464280	0.51	2/20
SCHEMBL7255758	0.50	2/20
SCHEMBL7254978	0.49	2/20
SCHEMBL2639659	0.48	2/20
SCHEMBL1036342	0.43	2/20
SCHEMBL4725978	0.43	2/20
SCHEMBL396186	0.42	2/20
SCHEMBL2056879	0.40	2/20
SCHEMBL7255012	0.40	2/20

Clinical trials — most relevant to SERPINH1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Metformin Use in Cardiac Fibrosis in PAI-1 Deficiency	PHASE4	ACTIVE_NOT_RECRUITING
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography	PHASE4	UNKNOWN
Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function	PHASE4	COMPLETED
Berinert P Study of Subcutaneous Versus Intravenous Administration	PHASE3	COMPLETED
International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema	PHASE2/PHASE3	COMPLETED
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency	PHASE3	COMPLETED
Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency	PHASE2/PHASE3	COMPLETED
A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema	PHASE3	COMPLETED
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks	PHASE3	COMPLETED
The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)	PHASE1/PHASE2	COMPLETED
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Kinetics, Efficacy and Safety of C1-Esteraseremmer-N	PHASE2	COMPLETED
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency	PHASE2	COMPLETED
Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery	PHASE1/PHASE2	UNKNOWN
Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers	PHASE1	COMPLETED
Identification and Characterization of Genetic Variants in Hereditary Angioedema	nan	NOT_YET_RECRUITING
Belgian Antithrombin Deficiency Registry	nan	NOT_YET_RECRUITING
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)	nan	COMPLETED
Epidemiological Analysis for Hereditary Angioedema Disease	nan	COMPLETED
Involvement of Monocytic B1 and B2 Receptors in Inflammation and Chronic Vascular Disease in Patients With Hereditary Bradykinetic Angioedema	nan	COMPLETED
C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks	nan	COMPLETED
Biomarker for Hereditary AngioEdema Disease	nan	COMPLETED
Genomic Research in Alpha-1 Antitrypsin Deficiency	nan	COMPLETED
Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals	nan	COMPLETED
Angioedema Biomarker Research Study	nan	UNKNOWN
Alpha-1 Carrier Genomics Study	nan	COMPLETED
Global Registry to Gather Data on Natural History of Patients With Hereditary Angioedema Type I and II	nan	UNKNOWN
Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)	nan	COMPLETED
Czech AATD Registry	nan	RECRUITING
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SERPINH1 binder may also engage these)

Protein	Name	Similarity
Q2KJH6	—	1.000	Q2KJH6 →
P19324	—	1.000	P19324 →
Q5RBS3	—	1.000	Q5RBS3 →
P29457	—	0.999	P29457 →
P13731	—	0.996	P13731 →
SERPINC1	Antithrombin-III	0.985	landscape →
P41361	—	0.980	P41361 →
P32262	—	0.979	P32262 →
Q5R5A3	—	0.979	Q5R5A3 →
P79335	—	0.978	P79335 →
P22777	—	0.978	P22777 →
P46202	—	0.977	P46202 →
P32261	—	0.977	P32261 →
Q9V3N1	—	0.976	Q9V3N1 →
Q94823	—	0.976	Q94823 →
P12393	—	0.975	P12393 →
P68566	—	0.975	P68566 →
Q00387	—	0.975	Q00387 →
P13909	—	0.974	P13909 →
P33831	—	0.974	P33831 →
Q6J201	—	0.974	Q6J201 →
Q9VFC2	—	0.974	Q9VFC2 →
P68565	—	0.973	P68565 →
P16708	—	0.973	P16708 →
Q27086	—	0.972	Q27086 →
Q0E8C8	—	0.971	Q0E8C8 →
Q5MIW3	—	0.971	Q5MIW3 →
A0A0K8RJV9	—	0.970	A0A0K8RJV9 →
A0A7H0DN13	—	0.969	A0A7H0DN13 →
P50449	—	0.969	P50449 →